09:02 AM EST - BioVaxys Technology Corp. : Announced that the Scientific Advisor for its CoviDTH program, Yvelise Barrios , MD, PhD, and Clinical Immunologist at Hospital Universitario de Canarias, Tenerife, Spain , has been invited to present her new clinical study entitled LONG TERM FOLLOW-UP OF IN VIVO CELLULAR IMMUNE RESPONSE TO SARS-CoV-2 USING DELAYED-TYPE HYPERSENSITIVITY CUTANEOUS TEST 1 at the 6 th European Congress of Immunology ("ECI") held September 1-4 , 2021. ECI is one of the most highly-regarded international conferences in the field of basic and clinical immunology. Two recovered patients were tested for DTH at 6 and 12 months after infection. The DTH responses were as follows: Subject A: 6 months=41mm, 12 months=35mm; Subject B: 6 months=14mm, 12 months=30mm. These are considered very large responses, compared, for example, to the DTH responses of people with a history of tuberculosis. These results pointed out that natural, acquired immunity in these two patients is still very clearly present after one year of follow-up and that the DTH is a very simple and easy to interpret test to answer questions about durability of cellular immune responses in COVID-19. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.31.
